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Abstract 
Short Communication on t(9;14)(q33;q32) 
IGH/LHX2, with data on clinics, and the genes 
implicated. 
Clinics and pathology 
Disease 
Chronic myeloid leukemia (CML) in B-cell 
lymphoid blast crisis 
Phenotype/cell stem origin 
B cell phenotype (CD19, CD10) with 2 aberrant 
myeloid markers (CD13 and CD33). 
Etiology 
Unknown. 
Epidemiology 
Only one case to date, a 10-year-old male patient 
(Nadal et al., 2012). 
Clinics 
Lymphadenopathies, enlarged spleen and liver. 
Central nervous system involvement. 
Cytology 
High WBC with blast cells (44%), myelemia, 
eosinophilia and basophilia. Bone marrow 
aspiration showed 60% of undifferentiated blast 
cells with persistence of the granulocytic lineage. 
Treatment 
The patient was treated according to the European 
protocol ESPHALL (imatinib, asparaginase, 
vincristine, vindesine, daunorubicin, aracytine, 
VP16, ifosfamide, and methotrexate, followed by 
an allograft). 
Evolution 
After induction, minimal residual disease (MRD) 
detection by CMF and by molecular analysis was 
negative, whereas RT-PCR for BCR-ABL1 
transcript was still positive. Chromosomal 
examination showed the presence of one metaphase 
out of 30 with only the t(9;22)(q34;q11), suggesting 
that the t(9;14) translocation was a secondary 
chromosomal abnormality. 
Thus, the chemotherapy had eradicated the 
lymphoblast cells but a CML clone persisted, 
further supporting the diagnosis of CML in BC.  
By 7 months after diagnosis, the patient underwent 
allogenic stem cell transplantation from his HLA-
matched sister. At 2 years post-transplantation, the 
patient was alive and well. BCR-ABL1 transcript 
was undetectable (<0.001%). 
Cytogenetics 
Additional anomalies 
The t(9;14)(q33;q32) translocation appears as a 
secondary abnormality occurring at acutisation of a 
CML with the usual t(9;22)(q34;q11) with a 
breakpoint in the mBCR region. The latest is 
usually observed in BCR-ABL1+ de novo acute 
lymphoblastic leukemia but is rare in CML.  
i(7)(q10), present in 2 out of the 20 metaphases 
analyzed using conventional karyotype, and in 
3/100 metaphases using FISH (7q22/7q36 Dual-
Color probe, Kreatech Diagnostics). 
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A. Conventional karyotype: partial R and G-banded karyotype. The derivative chromosomes of translocations t(9;14)(q33;q32) 
and t(9;22)(q34;q11) are denoted by solid and dotted arrows, respectively.  
B. FISH: representative metaphase hybridized with dual color break-apart IGH probe (Abbott, Rungis, France). A fusion signal is 
seen on normal chromosome 14 (large arrows), a red signal on derivative chromosome 14 (small solid arrows) and a green 
signal on derivative chromosome 9 (small dotted arrows).  
C. FISH: representative metaphase hybridized with a BCR/ABL ES probe (Abbott). A green signal is seen on a normal 
chromosome 22 (large arrows), and two fusion signals on derivative chromosomes 9 and 22 (small dotted arrows), confirming 
the BCR-ABL1 rearrangement with a breakpoint in the mBCR region. A red signal is observed on derivative chromosome 14 
(small solid arrows), indicating that the breakpoint of t(9;14) was centromeric to the ABL1 gene in chromosome 9. 
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Genes involved and 
proteins 
LHX2 
Location 
9q33 
Note 
LIM homeobox gene LHX2 is a member of the 
LIM homeobox family of transcription factors 
characterized by a DNA binding homeodomain and 
a cystein-rich LIM-domain. LHX2, initially 
identified as an early marker in B-lymphocyte 
differentiation (Xu et al., 1993), is involved in the 
neurogenesis, hair follicle, and hematopoietic 
development (Porter et al., 1997). 
IGH 
Location 
14q32 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
The translocation links sequence located 148 kb 
centromeric of LHX2 on chromosome 9 to JH6 
segment on chromosome 14. 
Fusion protein 
Note 
No fusion protein. 
Oncogenesis 
LHX2 juxtaposition with the IGH locus results in  
strong over-expression of LHX2, which may have 
contributed to the rapid progression in the blastic 
phase. It has been shown that over-expression of 
LHX2 in murine hematopoietic precursors leads to 
the development of chronic myeloproliferative 
disorders (Richter et al., 2003). Thus, 
transcriptional deregulation of LHX2 plays a 
recurrent role in leukemogenesis. 
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